Cerbios header

Cerbios header

X

[{"orgOrder":0,"company":"Imbrium Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Imbrium Therapeutics Presents First Data and Describes Novel Mechanism of Action For IMB-115","therapeuticArea":"Sleep","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Imbrium Therapeutics"},{"orgOrder":0,"company":"XWPharma","sponsor":"Panacea Venture","pharmaFlowCategory":"D","amount":"$40.0 million","upfrontCash":"Undisclosed","newsHeadline":"XWPharma Announces $40 Million Financing and Appoints Leonard Blum as Chief Executive Officer","therapeuticArea":"Sleep","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"XWPharma"},{"orgOrder":0,"company":"KemPharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"KemPharm Announces Full Data Set from Higher-Dose Serdexmethylphenidate (SDX) Phase 1 Clinical Trial","therapeuticArea":"Sleep","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"KemPharm"},{"orgOrder":0,"company":"KemPharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"KemPharm Doses First Subject in Phase 1 Clinical Trial Evaluating Cardiovascular Safety of Serdexmethylphenidate (SDX)","therapeuticArea":"Sleep","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"KemPharm"},{"orgOrder":0,"company":"Sumitomo","sponsor":"Jazz Pharmaceuticals","pharmaFlowCategory":"D","amount":"$1,140.0 million","upfrontCash":"$50.0 million","newsHeadline":"Jazz Pharmaceuticals and Sumitomo Pharma Announce Exclusive License Agreement to Develop and Commercialize DSP-0187, a Potent, Highly Selective Oral Orexin-2 Receptor Agonist","therapeuticArea":"Sleep","highestDevelopmentStatus":"Phase I","country":"JAPAN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Sumitomo"},{"orgOrder":0,"company":"KemPharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"KemPharm Announces Submission of Investigational New Drug Application for Phase 2 Trial of KP1077 in Idiopathic Hypersomnia (IH)","therapeuticArea":"Sleep","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"May 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"KemPharm"},{"orgOrder":0,"company":"Incannex Healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Positive Pre-IND Meeting with US FDA for IHL-42X for Obstructive Sleep Apnoea","therapeuticArea":"Sleep","highestDevelopmentStatus":"Phase I","country":"AUSTRALIA","productType":"Small molecule","productStatus":"Approved","date":"May 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Incannex Healthcare"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Filters

×

FILTER:

filter

Company

filter

Sponsor

filter

Country

filter

Product Type

filter

News Type

Active Filter(s):

Filters

Reset Filter

All Developments

Product Type

Companies

Incannex Healthcare

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Positive Pre-IND Meeting with US FDA for IHL-42X for Obstructive Sleep Apnoea

Details:

IHL-42X (dronabinol) is a fixed-dose combination of dronabinol and acetazolamide that is being developed as a treatment for obstructive sleep apnoea (‘OSA’) in adults.

Lead Product(s): Tetrahydrocannabinol,Acetazolamide

Therapeutic Area: Sleep Product Name: IHL-42X

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 17, 2022

ASK
US

Upload
your Pipeline Activity

KemPharm

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

KemPharm Announces Submission of Investigational New Drug Application for Phase 2 Trial of KP1077 in Idiopathic Hypersomnia (IH)

Details:

The data suggest that KP1077 (serdexmethylphenidate) produces a smoother, more gradual release of d-MPH that may avoid the adverse events associated with large and rapid exposure fluctuations that may be experienced with other stimulant-based therapies.

Lead Product(s): Serdexmethylphenidate

Therapeutic Area: Sleep Product Name: KP1077

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 05, 2022

ASK
US

Upload
your Pipeline Activity

Sumitomo

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Jazz Pharmaceuticals and Sumitomo Pharma Announce Exclusive License Agreement to Develop and Commercialize DSP-0187, a Potent, Highly Selective Oral Orexin-2 Receptor Agoni...

Details:

Under the agreement, Jazz will receive an exclusive license to develop and commercialize DSP-0187/JZP441 throughout the world except for Japan, China and other Asia/Pacific countries and regions, where Sumitomo Pharma will retain all development and commercialization rights.

Lead Product(s): DSP-0187

Therapeutic Area: Sleep Product Name: JZP441

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Jazz Pharmaceuticals

Deal Size: $1,140.0 million Upfront Cash: $50.0 million

Deal Type: Licensing Agreement May 04, 2022

ASK
US

Upload
your Pipeline Activity

KemPharm

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

KemPharm Doses First Subject in Phase 1 Clinical Trial Evaluating Cardiovascular Safety of Serdexmethylphenidate (SDX)

Details:

Prodrug of d-methylphenidate, is sole API in KP1077, a potential first-ever therapeutic treatment for Idiopathic Hypersomnia, a neurological disorder marked by significant, detrimental effects on nighttime sleep as well as daytime sleepiness/wakefulness.

Lead Product(s): Methylphenidate

Therapeutic Area: Sleep Product Name: KP1077

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 19, 2022

ASK
US

Upload
your Pipeline Activity

KemPharm

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

KemPharm Announces Full Data Set from Higher-Dose Serdexmethylphenidate (SDX) Phase 1 Clinical Trial

Details:

Data demonstrate higher doses of KP1077 (serdexmethylphenidate) prodrug of d-methylphenidate, were generally well-tolerated and produced targeted pharmacodynamic effects that may be beneficial for the treatment of idiopathic hypersomnia and other sleep disorders.

Lead Product(s): Serdexmethylphenidate

Therapeutic Area: Sleep Product Name: KP1077

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 21, 2022

ASK
US

Upload
your Pipeline Activity

XWPharma

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

XWPharma Announces $40 Million Financing and Appoints Leonard Blum as Chief Executive Officer

Details:

XWPharma expects to use proceeds to advance clinical development of the company’s lead investigational programs: XW10172, a GABAB receptor agonist intended for the treatment of sleep disorders in narcolepsy, Parkinson’s disease and other neurodegenerative diseases.

Lead Product(s): XW10172

Therapeutic Area: Sleep Product Name: XW10172

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Panacea Venture

Deal Size: $40.0 million Upfront Cash: Undisclosed

Deal Type: Series C Financing September 17, 2020

ASK
US

Upload
your Pipeline Activity

Imbrium Therapeutics

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Imbrium Therapeutics Presents First Data and Describes Novel Mechanism of Action For IMB-115

Details:

IMB-115 is a novel, highly potent and selective partial agonist for nociceptin/orphanin-FQ peptide (NOP) receptors designed to promote sleep onset and maintenance at doses that show minimal or no residual next-day somnolence (drowsiness) or psychomotor impairment.

Lead Product(s): IMB-115

Therapeutic Area: Sleep Product Name: IMB-115

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 28, 2020

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY